Proteomic identification of oxidatively modified retinal proteins in a chronic pressure-induced rat model of glaucoma

Investigative Ophthalmology and Visual Science

Volumn 46, Issue 9, 2005, Pages 3177-3187

  Tezel, Gülgün ^a   Yang, Xiangjun ^a   Cai, Jian ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DINITROPHENYLHYDRAZINE; ANAZOLENE SODIUM; ANTIBODY; CARBONYL DERIVATIVE; EYE PROTEIN; GLUTAMATE AMMONIA LIGASE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; GLYCOLYTIC ENZYME; HEAT SHOCK PROTEIN 72; PROTEIN HYDROLYSATE; SODIUM CHLORIDE;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY LABELING; ARTICLE; BIOINFORMATICS; CELL LOSS; CELLULAR DISTRIBUTION; COMPARATIVE STUDY; CONTROLLED STUDY; EXCITOTOXICITY; GLAUCOMA; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; LIQUID CHROMATOGRAPHY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOLECULAR WEIGHT; NERVE DEGENERATION; NONHUMAN; OCULAR BLOOD VESSEL; OXIDATION; OXIDATIVE STRESS; PATHOGENESIS; PEPTIDE MASS FINGERPRINTING; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN MODIFICATION; PROTEOMICS; RAT; RETINA; TANDEM MASS SPECTROMETRY; TWO DIMENSIONAL OXYBLOT ANALYSIS; VALIDATION PROCESS; WESTERN BLOTTING; ANIMAL; BROWN NORWAY RAT; CELL COUNT; CHRONIC DISEASE; DISEASE MODEL; FLUORESCENT ANTIBODY TECHNIQUE; MASS SPECTROMETRY; METABOLISM; NERVE FIBER; OPTIC NERVE; OPTIC NERVE DISEASE; OXIDATION REDUCTION REACTION; PATHOLOGY; PEPTIDE MAPPING; TWO DIMENSIONAL GEL ELECTROPHORESIS;

ANIMALS; AXONS; CELL COUNT; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; EYE PROTEINS; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GLAUCOMA; INTRAOCULAR PRESSURE; MALE; OPTIC NERVE; OPTIC NERVE DISEASES; OXIDATION-REDUCTION; PEPTIDE MAPPING; PROTEOMICS; RATS; RATS, INBRED BN; RETINA; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 27244444388     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.05-0208     Document Type: Article

References (79)

1. Green D, Kroemer G. The central executioners of apoptosis: caspases or mitochondria? Trends Cell Biol. 1998;8:267-271.
2. Xiang J, Chao DT, Korsmeyer SJ. BAX-induced cell death may not require interleukin 1 beta-converting enzyme-like proteases. Proc Natl Acad Sci USA. 1996;93:14559-14563.
3. Cai J, Jones DP. Superoxide in apoptosis: mitochondrial generation triggered by cytochrome c loss. J Biol Chem. 1998;273:11401-11404.
4. Mittag TW, Danias J, Pohorenec G, et al. Retinal damage after 3 to 4 months of elevated intraocular pressure in a rat glaucoma model. Invest Ophthalmol Vis Sci. 2000;41:3451-3459.
5. Tatton WG, Chalmers-Redman RM, Sud A, Podos SM, Mittag TW. Maintaining mitochondrial membrane impermeability: an opportunity for new therapy in glaucoma? Surv Ophthalmol. 2001;45(suppl 3):S277-S283; discussion S295-2276.
6. Ko ML, Hu DN, Ritch R, Sharma SC. The combined effect of brain-derived neurotrophic factor and a free radical scavenger in experimental glaucoma. Invest Ophthalmol Vis Sci. 2000;41:2967-2971.
7. Kortuem K, Geiger LK, Levin LA. Differential susceptibility of retinal ganglion cells to reactive oxygen species. Invest Ophthalmol Vis Sci. 2000;41:3176-3182.
8. Geiger LK, Kortuem KR, Alexejun C, Levin LA. Reduced redox state allows prolonged survival of axotomized neonatal retinal ganglion cells. Neuroscience. 2002;109:635-642.
9. Tezel G, Yang X. Caspase-independent component of retinal ganglion cell death, in vitro. Invest Ophthalmol Vis Sci. 2004;45:4049-4059.
10. Tezel G, Hernandez MR, Wax MB. Immunostaining of heat shock proteins in the retina and optic nerve head of normal and glaucomatous eyes. Arch Ophthalmol. 2000;118:511-518.
11. Yan X, Tezel G, Wax MB, Edward DP. Matrix metalloproteinases and tumor necrosis factor alpha in glaucomatous optic nerve head. Arch Ophthalmol. 2000;118:666-673.
12. Tezel G, Li LY, Patil RV, Wax MB. Tumor necrosis factor-alpha and its receptor-1 in the retina of normal and glaucomatous eyes. Invest Ophthalmol Vis Sci. 2001;42:1787-1794.
13. Tezel G, Chauhan BC, LeBlanc RP, Wax MB. Immunohistochemical assessment of the glial mitogen-activated protein kinase activation in glaucoma. Invest Ophthalmol Vis Sci. 2003;44:3025-3033.
14. Tezel G, Wax MB. Hypoxia-inducible factor !alpha in the glaucomatous retina and optic nerve head. Arch Ophthalmol. 2004;122:1348-1356.
15. Tezel G, Wax MB. Inhibition of caspase activity in retinal cell apoptosis induced by various stimuli in vitro. Invest Ophthalmol Vis Sci. 1999;40:2660-2667.
16. Tezel G, Wax MB. Increased production of tumor necrosis factor-alpha by glial cells exposed to simulated ischemia or elevated hydrostatic pressure induces apoptosis in cocultured retinal ganglion cells. J Neurosci. 2000;20:8693-8700.
17. McKinnon SJ, Lehman DM, Kerrigan-Baumrind IA, et al. Caspase activation and amyloid precursor protein cleavage in rat ocular hypertension. Invest Ophthalmol Vis Sci. 2002;43:1077-1087.
18. Tezel G, Yang X. Comparative gene array analysis of TNF-α-induced MAPK and NF-κB signaling pathways between retinal ganglion cells and glial cells. Exp Eye Res. 2005;81:207-217.
19. Gygi SP, Rochon Y, Franza BR, Aebersold R. Correlation between protein and mRNA abundance in yeast. Mol Cell Biol. 1999;19:1720-1730.
20. Pandey A, Mann M. Proteomics to study genes and genomes. Nature. 2000;405:837-846.
21. Morrison JC, Moore CG, Deppmeier LM, Gold BG, Meshul CK, Johnson EC. A rat model of chronic pressure-induced optic nerve damage. Exp Eye Res. 1997;64:85-96.
22. Jia L, Cepurna WO, Johnson EC, Morrison JC. Effect of general anesthetics on IOP in rats with experimental aqueous outflow obstruction. Invest Ophthalmol Vis Sci. 2000;41:3415-3419.
23. McKinnon SJ, Lehman DM, Tahzib NG, et al. Baculoviral IAP repeat-containing-4 protects optic nerve axons in a rat glaucoma model. Mol Ther. 2002;5:780-787.
24. Chauhan BC, Pan J, Archibald ML, LeVatte TL, Kelly ME, Tremblay F. Effect of intraocular pressure on optic disc topography, electroretinography, and axonal loss in a chronic pressure-induced rat model of optic nerve damage. Invest Ophthalmol Vis Sci. 2002;43:2969-2976.
25. Sanchez RM, Dunkelberger GR, Quigley HA. The number and diameter distribution of axons in the monkey optic nerve. Invest Ophthalmol Vis Sci. 1986;27:1342-1350.
26. Castegna A, Aksenov M, Thongboonkerd V, et al. Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part II: dihydropyrimidinase-related protein 2, alpha-enolase and heat shock cognate 71. J Neurochem. 2002;82:1524-1532.
27. Tezel G, Wax MB. The mechanisms of HSP27 antibody-mediated apoptosis in retinal neuronal cells. J Neurosci. 2000;20:3552-3562.
28. Thongboonkerd V, Gozal E, Sachleben LR Jr, et al. Proteomic analysis reveals alterations in the renal kallikrein pathway during hypoxia-induced hypertension. J Biol Chem. 2002;277:34708-34716.
29. Pappin DJ. Peptide mass fingerprinting using MALDI-TOF mass spectrometry. Methods Mol Biol. 1997;64:165-173.
30. Tezel G, Yang X, Yang J, Wax MB. Role of tumor necrosis factor receptor-1 in the death of retinal ganglion cells following optic nerve crush injury in mice. Brain Res. 2004;996:202-212.
31. Smith MA, Sayre LM, Anderson VE, et al. Cytochemical demonstration of oxidative damage in Alzheimer disease by immunochemical enhancement of the carbonyl reaction with 2,4-dinitrophenylhydrazine. J Histochem Cytochem. 1998;46:731-735.
32. Schlamp CL, Johnson EC, Li Y, Morrison JC, Nickells RW. Changes in Thy1 gene expression associated with damaged retinal ganglion cells. Mol Vis. 2001;7:192-201.
33. Shacter E. Quantification and significance of protein oxidation in biological samples. Drug Metab Rev. 2000;32:307-326.
34. Butterfield DA. Proteomics: a new approach to investigate oxidative stress in Alzheimer's disease brain. Brain Res. 2004;1000:1-7.
35. Smith CD, Carney JM, Starke-Reed PE, et al. Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease. Proc Natl Acad Sci USA. 1991;88:10540-10543.
36. Stadtman ER. Protein oxidation and aging. Science. 1992;257:1220-1224.
37. Berlett BS, Stadtman ER. Protein oxidation in aging, disease, and oxidative stress. J Biol Chem. 1997;272:20313-203l6.
38. Castegna A, Aksenov M, Aksenova M, et al. Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part I: creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. Free Radic Biol Med. 2002;33:562-571.
39. Gu X, Meer SG, Miyagi M, et al. Carboxyethylpyrrole protein adducts and autoantibodies, biomarkers for age-related macular degeneration. J Biol Chem. 2003;278:42027-42035.
40. Hirose F, Kiryu J, Miyamoto K, et al. In vivo evaluation of retinal injury after transient ischemia in hypertensive rats. Hypertension. 2004;43:1098-1102.
41. Osborne NN, Casson RJ, Wood JP, Chidlow G, Graham M, Melena J. Retinal ischemia: mechanisms of damage and potential therapeutic strategies. Prog Retin Eye Res. 2004;23:91-147.
42. Davies KJ. Degradation of oxidized proteins by the 20S proteasome. Biochimie (Paris). 2001;83:301-310.
43. Dean RT, Fu S, Stocker R, Davies MJ. Biochemistry and pathology of radical-mediated protein oxidation. Biochem J. 1997;324:1-18.
44. Sirover MA. New insights into an old protein: the functional diversity of mammalian glyceraldehyde-3-phosphate dehydrogenase. Biochim Biophys Acta. 1999;1432:159-184.
45. Hyslop PA, Hinshaw DB, Halsey WA Jr, et al. Mechanisms of oxidant-mediated cell injury: the glycolytic and mitochondrial pathways of ADP phosphorylation are major intracellular targets inactivated by hydrogen peroxide. J Biol Chem. 1988;263:1665-1675.
46. Arutyunov DY, Muronetz VI. The activation of glycolysis performed by the non-phosphorylating glyceraldehyde-3-phosphate dehydrogenase in the model system. Biochem Biophys Res Commun. 2003;300:149-154.
47. Winkler BS, Starnes CA, Sauer MW, Firouzgan Z, Chen SC. Cultured retinal neuronal cells and Müller cells both show net production of lactate. Neurochem Int. 2004;45:311-320.
48. Sawa A, Khan AA, Hester LD, Snyder SH. Glyceraldehyde-3-phosphate dehydrogenase: nuclear translocation participates in neuronal and nonneuronal cell death. Proc Natl Acad Sci USA. 1997;94:11669-11674.
49. Chen RW, Saunders PA, Wei H, Li Z, Seth P, Chuang DM. Involvement of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and p53 in neuronal apoptosis: evidence that GAPDH is upregulated by p53. J Neurosci. 1999;19:9654-9662.
50. Dastoor Z, Dreyer JL. Potential role of nuclear translocation of glyceraldehyde-3-phosphate dehydrogenase in apoptosis and oxidative stress. J Cell Sci. 2001;114:1643-1653.
51. Chuang DM, Ishitani R. A role for GAPDH in apoptosis and neurodegeneration. Nat Meet. 1996;2:609-610.
52. Mazzola JL, Sirover MA. Reduction of glyceraldehyde-3-phosphate dehydrogenase activity in Alzheimer's disease and in Huntington's disease fibroblasts. J Neurochem. 2001;76:442-449.
53. Tatton WG, Chalmers-Redman R, Brown D, Tatton N. Apoptosis in Parkinson's disease: signals for neuronal degradation. Ann Neurol. 2003;53(suppl 3):S61-S70; discussion S70-S62.
54. Tatton WG, Chalmers-Redman RM, Elstner M, et al. Glyceraldehyde-3- phosphate dehydrogenase in neurodegeneration and apoptosis signaling. J Neural Transm Suppl. 2000;60:77-100.
55. Tatton NA. Increased caspase 3 and Bax immunoreactivity accompany nuclear GAPDH translocation and neuronal apoptosis in Parkinson's disease. Exp Neurol. 2000;166:29-43.
56. Arutyunova EI, Danshina PV, Domnina LV, Pleten AP, Muronetz VI. Oxidation of glyceraldehyde-3-phosphate dehydrogenase enhances its binding to nucleic acids. Biochem Biophys Res Commun. 2003;307:547-552.
57. Evguenieva-Hackenberg E, Schiltz E, Klug G. Dehydrogenases from all three domains of life cleave RNA. J Biol Chem. 2002;277:46145-46150.
58. Pelham HR. Speculations on the functions of the major heat shock and glucose-regulated proteins. Cell. 1986;46:959-961.
59. Chirico WJ, Waters MG, Blobel G. 70K heat shock related proteins stimulate protein translocation into microsomes. Nature. 1988;332:805-810.
60. Chiang HL, Terlecky SR, Plant CP, Dice JF. A role for a 70-kilodalton heat shock protein in lysosomal degradation of intracellular proteins. Science. 1989;246:382-385.
61. Caprioli J, Kitano S, Morgan JE. Hyperthermia and hypoxia increase tolerance of retinal ganglion cells to anoxia and excitotoxicity. Invest Ophthalmol Vis Sci. 1996;37:2376-2381.
62. Park KH, Cozier F, Ong OC, Caprioli J. Induction of heat shock protein 72 protects retinal ganglion cells in a rat glaucoma model. Invest Ophthalmol Vis Sci. 2001;42:1522-1530.
63. Ishil Y, Kwong JM, Caprioli J. Retinal ganglion cell protection with geranylgeranylacetone, a heat shock protein inducer, in a rat glaucoma model. Invest Ophthalmol Vis Sci. 2003;44:1982-1992.
64. Steel R, Doherty JP, Buzzard KA, demons NJ, Hawkins CJ, Anderson RL. HSP72 inhibits apoptosis upstream of the mitochondria and not through interactions with Apaf-1. J Biol Chem. 2004;279:51490-51499.
65. Beere HM, Wolf BB, Cain K, et al. Heat-shock protein 70 inhibits apoptosis by preventing recruitment of procaspase-9 to the Apaf-1 apoptosome. Nat Cell Biol. 2000;2:469-475.
66. Li CY, Lee JS, Ko YG, Kim JI, Seo JS. HSP70 inhibits apoptosis downstream of cytochrome c release and upstream of caspase-3 activation. J Biol Chem. 2000;275:25665-25671.
67. Ravagnan L, Gurbuxani S, Susin SA, et al. Heat-shock protein 70 antagonizes apoptosis-inducing factor. Nat Cell Biol. 2001;3:839-843.
68. Levine RL. Oxidative modification of glutamine synthetase. I. Inactivation is due to loss of one histidine residue. J Biol Chem. 1983;258:11823-11827.
69. Oliver CN, Starke-Reed PE, Stadtman ER, Liu GJ, Carney JM, Floyd RA. Oxidative damage to brain proteins, loss of glutamine synthetase activity, and production of free radicals during ischemia/reperfusion-induced injury to gerbil brain. Proc Natl Acad Sci USA. 1990;87:5144-5147.
70. Butterfield DA, Hensley K, Cole P, et al. Oxidatively induced structural alteration of glutamine synthetase assessed by analysis of spin label incorporation kinetics: relevance to Alzheimer's disease. J Neurochem. 1997;68:2451-2457.
71. Linser PJ, Sorrentino M, Moscona AA. Cellular compartmentalization of carbonic anhydrase-C and glutamine synthetase in developing and mature mouse neural retina. Brain Res. 1984;315:65-71.
72. Newman E, Reichenbach A. The Muller cell: a functional element of the retina. Trends Neurosci. 1996;19:307-312.
73. Carter-Dawson L, Crawford ML, Harwerth RS, et al. Vitreal glutamate concentration in monkeys with experimental glaucoma. Invest Ophthalmol Vis Sci. 2002;43:2633-2637.
74. Levkovitch-Verbin H, Martin KR, Quigley HA, Baumrind LA, Pease ME, Valenta D. Measurement of amino acid levels in the vitreous humor of rats after chronic intraocular pressure elevation or optic nerve transection. J Glaucoma. 2002;11:396-405.
75. Honkanen RA, Baruah S, Zimmerman MB, et al. Vitreous amino acid concentrations in patients with glaucoma undergoing vitrectomy. Arch Ophthalmol. 2003;121:183-188.
76. Wamsley S, Gabelt BT, Dahl DB, et al. Vitreous glutamate concentration and axon loss in monkeys with experimental glaucoma. Arch Ophthalmol. 2005;123:64-70.
77. Dreyer EB, Zurakowski D, Schumer RA, Podos SM, Lipton SA. Elevated glutamate levels in the vitreous body of humans and monkeys with glaucoma. Arch Ophthalmol. 1996;114:299-305.
78. Shen F, Chen B, Danias J, et al. Glutamate-induced glutamine synthetase expression in retinal Muller cells after short-term ocular hypertension in the rat. Invest Ophthalmol Vis Sci. 2004;45:3107-3112.
79. Gomez-Baena G, Diez J, Garcia-Fernandez JM, El Alaoui S, Humanes L. Regulation of glutamine synthetase by metal-catalyzed oxidative modification in the marine oxyphotobacterium prochlorococcus. Biochim Biophys Acta. 2001;1568:237-244.